4-FMA

4-Fluoromethamphetamine

para-Fluoromethamphetamine

Psychoactive Class

Chemical Class

4-FMA is a novel stimulant-entactogen of the substituted amphetamine class, chemically related to both methamphetamine and 4-fluoroamphetamine. First detected in Japanese legal high markets in 2006, it gained wider popularity as a research chemical after 4-FA was banned in the Netherlands in 2017.¹ User reports describe its effects as combining traditional stimulant and entactogenic qualities, subjectively situated between 4-FA and 2-FMA. Little is known about its pharmacology or toxicology.

Dosage & Duration

Dosage

Threshold~10 mg

Light25-50 mg

Moderate50-75 mg

Strong100-125 mg

Heavy125+ mg

Duration

Onset20-40 minutes

Come Up20-40 minutes

Peak2-5 hours

Offset1-2 hours

After Effects3-12 hours

Total4-8 hours

Subjective Effects

4-FMA produces a stimulating experience broadly comparable to other substituted amphetamines, characterized by euphoria, mood lift, and a marked increase in energy and alertness. Users become notably more sociable and talkative, with heightened sexuality also reported. The experience carries a distinctly stimulant-typical profile in which wakefulness persists well beyond the desired duration, and at heavier use hallucinations, aggressiveness, and mood instability can emerge.

Physical

The body load is that of a typical stimulant: increased energy, decreased appetite, and a reduced need for sleep, accompanied by sweating, jaw tension, itchiness, and disturbed sleep patterns after the experience ends.

Uncomfortable

Increased perspirationItchiness

Cognitive

The headspace is energetic and socially disinhibited, marked by mood lift, euphoria, and excessive talking. This can shift toward moodiness and aggressiveness, especially as the experience progresses or with repeated dosing.

Emotional

Enhancements

Visual

Visual effects are largely absent at typical doses, though hallucinations have been reported with heavy use.

Auditory

Auditory hallucinations

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

4-FMA is thought to act as a releasing agent and reuptake inhibitor of serotonin, dopamine, and norepinephrine.² It binds to and partially blocks the monoamine transporter proteins, increasing the synaptic concentration of all three neurotransmitters.² Relatively little formal pharmacological research has been conducted on 4-FMA, and its proposed mechanism is largely inferred from its structural relationship to other fluorinated amphetamines.

Pharmacokinetics

Very little is known about the metabolism of 4-FMA. It has been identified as a CYP450 enzyme inhibitor, a property that has been shown to reduce the metabolism of methamphetamine when the two are present together.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

2C-T-x compounds5-MeO-xxT tryptaminesAMTAlcoholCaffeineCannabisCocaineDOx compoundsDXMKetamineMAOIsMethoxetamineNBOMe compoundsOpioidsPCPTramadol

TripSit

Tolerance

Full Tolerance

Many effects can become less responsive after prolonged repeated use, leading users to need higher doses for similar results.

Baseline Reset

1-2 weeks for stimulant effects; tolerance to entactogenic effects may take longer to return to baseline.

Half Tolerance

3-7 days

Cross Tolerance

Dopaminergic stimulants

Harm Potential

Addiction & Dependence

Psychological

Moderate

4-FMA is described as having moderate addictive potential and high abuse liability, and psychological dependence may develop in some users.³ Reports also identify compulsive redosing as a notable cognitive effect.

Physical

Cravings and withdrawal effects may occur if chronic users suddenly stop usage, though specific physical withdrawal symptoms have not been characterized in the available literature.

Toxicity

Cardiovascular

4-FMA is reported to produce more cardiovascular side effects than similar fluorinated amphetamines; serious cardio- and cerebrovascular complications have been documented including arrhythmias, conduction disturbances, and acute cardiac failure, typically in the context of higher doses or pre-existing cardiovascular conditions.⁴

Central Nervous System

4-FMA may produce damage to the brain and carries increased risks for neurotoxicity; however, the actual extent of this risk and whether it causes long-lasting serotonin depletion like some related compounds remains unstudied.

Nasal and Pharyngeal Mucosa

4-FMA is particularly caustic compared to other compounds and can cause chemical burns within the nasal passage and throat when insufflated.

Psychosis Risk

Abuse of amphetamine-class compounds at high dosages for prolonged periods can result in stimulant psychosis presenting with paranoia, hallucinations, or delusions.⁶ Approximately 5-15% of users who develop stimulant psychosis fail to recover completely.⁶ Psychosis very rarely arises from occasional or therapeutic use patterns.

History & Culture

4-Fluoromethamphetamine first emerged in documented form when it was detected in legal high products sold in Japanese markets in 2006. Japan subsequently moved to regulate the compound in 2008, prohibiting its sale and possession with intent to distribute while stopping short of criminalizing…

Legality

By Country

United StatesUnscheduled (Analogue Act applies)

Not specifically scheduled at the federal level. However, as a structural analogue of methamphetamine, sale or possession could be prosecuted under the Federal Analogue Act when intended for human consumption.¹⁵

AustriaIllegal (NPSG)

Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act).⁸ Possession, production, and sale are prohibited.

ChinaControlled substance

Designated a controlled substance as of October 2015 under national drug control legislation.¹⁰

FranceNot explicitly scheduled

As of December 2024, not specifically listed in controlled substance schedules. Exists in a legal grey area where possession may be permitted but regulatory status remains ambiguous.

ItalySchedule I

Listed as a Schedule I controlled substance under Italian drug legislation.¹² Production, sale, and possession are prohibited.

New ZealandSchedule 3 (Class C)

Controlled as an amphetamine analogue under the Misuse of Drugs Act.¹³ Schedule 3 substances carry penalties for possession, supply, and manufacture.

United KingdomClass A

Controlled under the Misuse of Drugs Act 1971, added through the 1977 amendment covering fluorinated amphetamine derivatives.¹⁴ Class A designation carries the most severe penalties including up to 7 years imprisonment for possession.

AustraliaSchedule 9

Prohibited substance under the Poisons Standard.⁷ This category applies to substances with abuse or misuse potential; manufacture, possession, sale, and use are meant to be legally barred except for health-authority-approved medical or scientific research, analysis, teaching, or training.

CanadaSchedule I (analogue)

Controlled since 1996 as an analogue of methamphetamine.⁹ Falls under the Controlled Drugs and Substances Act with associated criminal penalties for possession, trafficking, and production.

FinlandScheduled (narcotic)

Listed in the government decree on narcotic substances, preparations and plants. Possession and distribution are illegal under Finnish narcotics law.

GermanyAnlage II BtMG

Controlled under Schedule II of the Betäubungsmittelgesetz (Narcotics Act) since July 26, 2012.¹¹ Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.

JapanControlled substance

First detected in legal highs sold in 2006. Since 2008, illegal to sell or possess with intent to distribute, though simple possession for personal use is not criminalized.

SwitzerlandControlled (Verzeichnis E)

Specifically named as a controlled substance under Verzeichnis E of the Swiss narcotics regulations. Unauthorized handling is prohibited.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 4-FMA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

4-FMA

4-Fluoromethamphetamine

para-Fluoromethamphetamine

Psychoactive Class

Stimulant Entactogen

Chemical Class

Amphetamine (substituted)